Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review

Abstract

BackgroundThe cumulative effect of taking multiple medicines with anticholinergic properties termed as anticholinergic burden can adversely impact cognition, physical function and increase the risk of mortality. Expert opinion derived risk scales are routinely used in research and clinical practice to quantify anticholinergic burden. These scales rank the anticholinergic activity of medicines into four categories, ranging from no anticholinergic activity (= 0) to definite/high anticholinergic activity (= 3). The aim of this systematic review was to compare anticholinergic burden quantified by the anticholinergic risk scales and evaluate associations with adverse outcomes in older people.MethodsWe conducted a literature search in Ovid MEDLINE, EMBASE and PsycINFO from 1984-2014 to identify expert opinion derived anticholinergic risk scales. In addition to this, a citation analysis was performed in Web of Science and Google Scholar to track prospective citing of references of selected articles for assessment of individual scales for adverse anticholinergic outcomes. The primary outcomes of interest were functional and cognitive outcomes associated with anticholinergic burden in older people. The critical appraisals of the included studies were performed by two independent reviewers and the data were extracted onto standardised forms.ResultsThe primary electronic literature search identified a total of 1250 records in the 3 different databases. On the basis of full-text analysis, we identified 7 expert-based anticholinergic rating scales that met the inclusion criteria. The rating of anticholinergic activity for medicines among these rating scales was inconsistent. For example, quetiapine was rated as having high anticholinergic activity in one scale (n = 1), moderate in another scale (n = 1) and low in two other scales (n = 2). Citation analysis of the individual scales showed that the Anticholinergic Cognitive Burden (ACB) scale was the most frequently validated expert based anticholinergic scale for adverse outcomes (N = 13).ConclusionsIn conclusion, there is not one standardised tool for measuring anticholinergic burden. Cohort studies have shown that higher anticholinergic burden is associated with negative brain effects, poorer cognitive and functional outcomes.Electronic supplementary materialThe online version of this article (doi:10.1186/s12877-015-0029-9) contains supplementary material, which is available to authorized users.

Legal implications of deprescribing: a case scenario

“…Provided a patient is made aware of all material risks and reasonable alternatives then a prescriber is likely to satisfy the test for informed consent. While prescribers have access to a variety of tools to support safe deprescribing, [12][13][14][15][16] and alternative treatments are available for many conditions, the challenge is how we identify risks that are material to our patients. Patientcentred conversations 17 in the context of structured review 18 may support embedding this in our daily practice.…”

Analysis of spatiotemporal pattern and quantification of gastrointestinal slow waves caused by anticholinergic drugs

“…44,45 Both these drugs have strong anticholinergic activity, as rated on anticholinergic risk scales, 39,[43][44][45][46] and are typical drugs that may be used long-term by patients. The relationship of anticholinergic drugs, the parasympathetic nervous system, and the enteric nervous system is shown in Fig.…”

“…A supratherapeutic concentration was then added, allowed to equilibrate for 5 minutes, and then recorded for 5 minutes. 46 Wong et al…”

Análise dos medicamentos relaxantes musculares de ação central comercializados no Brasil na perspectiva do Cuidado ao Idoso

“…al. 27 , e pesquisouse também a presença do fármaco na lista de medicamentos de alta atividade anticolinérgica incluída nos Critérios de Beers 28 . As informações sobre as reações adversas a medicamentos e outros aspectos relacionados à segurança foram pesquisados na bula versão para o paciente.…”